Prenetics Global Limited Announces Its IM8 Health And Longevity Brand Achieved A Record $108M In Annualized Recurring Revenue In October

October Revenue Grew 32% MoM and on Track to hit $10 Million in Monthly Revenue by December 2025 ~

 Prenetics Global Limited (NASDAQ:PRE) ("Prenetics"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced a record breaking month for IM8 in October, reaching approximately $108 million in annualized recurring revenue (ARR) just 11 months after its commercial launch. Building on the momentum from last week's successful $44 million equity offering, IM8 is positioned for accelerated global expansion and enhanced partnerships.

Key highlights:

• IM8 delivered its strongest month to date in October with $9 million in monthly revenue, representing 32% month-over-month growth from September's $6.8 million, driven by strong subscriber growth, elevated average order value and improved retention metrics.
• Demonstrating accelerating growth trajectory, IM8 achieved an all-time high single-day revenue record of $400,000 last week.
• Based on current trajectory, IM8 projects a minimum of $10 million in monthly revenue by December 2025.
• The IM8 brand has delivered 13 million servings to more than 420,000 customers, across 31 countries since launch.
• 80% of all new orders are subscribers directly through the IM8 website.
• 11 Months Post launch, IM8's ARR stands at approximately $108 million: a milestone indicating strong product-market fit and execution across direct-to-consumer and global markets.
• The recent launch of Daily Ultimate Longevity has driven significant momentum, with average order value increasing from ~$110 to ~$145, reflecting robust consumer demand for IM8's premium product offerings.